News

What pharma R&D lab managers and QA leads should have in place before the alarm sounds When your lab freezer starts to alarm, it can be easy to panic. You need a clear, actionable plan in place to protect irreplaceable...

Early-stage companies tend to focus on the science and the next funding round. The regulatory plan often comes later, sometimes after a first study is already designed. That order is understandable, but it can be expensive, because the pathway...

BioNTech SE has officially entered into a clinical trial collaboration and supply agreement with Gilead Sciences Inc. to evaluate the bispecific immunomodulator pumitamig in combination with the TROP2-directed antibody-drug conjugate (ADC) sacituzumab govitecan. Announced on October 22, 2026, this...

Cencora has signed a definitive agreement to acquire American Oncology Network, a physician-led network of more than 350 oncology providers operating across 21 states, in a transaction that values AON at approximately $2.4 billion. The deal is set to...

Merck KGaA has entered into an agreement to acquire British biotech Silence Therapeutics for $1.3 billion in a fully cash-based transaction, securing the German pharmaceutical company's access to a compelling short interfering RNA (siRNA) drug development platform and a...

Chronic inflammation underlies a surprisingly wide range of diagnoses: autoimmune flares, unexplained fatigue, hormonal disruption, stubborn weight gain. People who've cycled through standard appointments without lasting relief will find that functional medicine clinics in Denver for a personalized approach...

METiS TechBio has announced a strategic collaboration with Eli Lilly and Company to research and develop next-generation lipid nanoparticle (LNP)-based delivery solutions, leveraging METiS's proprietary AI-driven platform to enable precise, tissue-specific delivery of therapeutic modalities. Under the terms of the...